Are there any biomarkers for SHP2 activity in cancer?
Researchers are actively investigating biomarkers that can indicate SHP2 activity. These biomarkers could help identify patients who are more likely to benefit from SHP2 inhibitors. For example, the presence of specific PTPN11 mutations or elevated levels of phosphorylated downstream targets could serve as potential biomarkers.
